ER-100
AssetGene therapyAlso ER-100 epigenetic therapy
AAV-delivered, inducible OSK gene therapy for epigenetic reprogramming and cellular rejuvenation.
- Stage
- Phase 1
- Modality
- Gene therapy
- Target
- SOX2
- Indications
- 4
- Trials
- 1
- Developers
- 1
Indications
4Glaucoma
Phase 1lifebiosciences.com7 Oct 2026
NAION
Phase 1lifebiosciences.com7 Oct 2026
Naion( non-arteritic anterior ischemic optic neuropathy)
Phase 1RECRUITINGNCT07290244clinicaltrials.gov7 Oct 2026
1 more
- Targets and what it contains4
- Owner and partners1
- Trials1
- Evidence for its targets4
- Competitors7
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources